Blood-filtering therapy may slow lung decline in transplant patients
NCT ID NCT02181257
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests a treatment called extracorporeal photopheresis (ECP) for lung transplant patients who develop bronchiolitis obliterans syndrome (BOS), a form of chronic rejection. ECP involves filtering a patient's blood, treating it with a light-sensitive drug, and returning it to the body. The study aims to see if ECP can slow the decline in lung function or improve survival. About 280 Medicare-eligible adults are enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Extracorporeal photopheresis (ECP) with methoxsalen
What this could lead to
If successful, ECP could become a standard treatment to slow lung function decline in lung transplant patients with bronchiolitis obliterans syndrome.
What could go wrong
This is a phase 3 trial, but results are not yet final. The treatment is complex and may not work for all patients, and there are risks from the procedure and methoxsalen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS SYNDROME (BOS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Columbia University
New York, New York, 10032, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Houston Methodist
Houston, Texas, 77030, United States
-
Indiana University Health
Indianapolis, Indiana, 46202, United States
-
Inova Health System
Falls Church, Virginia, 22042, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Spectrum Health
Grand Rapids, Michigan, 45903, United States
-
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013, United States
-
Temple University
Philadelphia, Pennsylvania, 19140, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35226, United States
-
University of California San Diego
La Jolla, California, 92093, United States
-
University of Florida
Gainsville, Florida, 32610, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Kentucky
Lexington, Kentucky, 40506, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
University of Minnesota Medical Center, Fairview
Minneapolis, Minnesota, 55455, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States